Overview
NICE is unable to make a recommendation about the use in the NHS of elotuzumab for previously treated multiple myeloma. This is because Bristol–Myers Squibb did not provide an evidence submission.
Last reviewed: 22 March 2017
Next review: We will review this decision if the company decides to make a submission